Abstract
This paper examines the implications of parallel trade for the level of innovations in health care market, the price of the innovated drug and for welfare levels of the Third and the Rich world. We have shown in terms of a very simple analytical framework that regardless of intra country differences, parallel imports results in lower level of health-care innovation but, contrary to popular as well as conventional theoretical wisdom, lower price in the third world compared to market-based discrimination. Despite such lower price, however, parallel imports unambiguously makes all buyers in the Third world worse off when intra-country income disparity exist. The only gainers from parallel imports appear to be the buyers in the rich world.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
